Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

9.73
-0.0500-0.51%
Post-market: 9.730.00000.00%16:10 EDT
Volume:1.24M
Turnover:12.02M
Market Cap:848.04M
PE:-4.57
High:9.93
Open:9.86
Low:9.44
Close:9.78
52wk High:36.26
52wk Low:6.65
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.95
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:1.97
PE(LYR):-5.20

Loading ...

Olema Pharma Director Cyrus Harmon Sells $292,412 of Common Shares

Reuters
·
Jul 28

Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?

Simply Wall St.
·
Jul 03

Olema Grants Stock Options for 215,800 Shares to Eight New Employees Under Inducement Plan

Reuters
·
Jul 03

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Olema Pharmaceuticals shareholders elect four directors at annual meeting

Reuters
·
Jun 24

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 09

LifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Jun 06

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

TIPRANKS
·
Jun 06

UBS Remains a Buy on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Jun 05

Olema grants 176,150 inducement stock options at $12.71 per share

Reuters
·
Jun 03

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Olema Pharmaceuticals (OLMA) Gets a Buy from Guggenheim

TIPRANKS
·
Jun 01

Olema Pharmaceuticals: Buy Rating Reiterated as Pipeline Progress Supports Attractive Risk/Reward with Unchanged $62 Price Target

TIPRANKS
·
Jun 01

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (OLMA) and CG Oncology, Inc. (CGON)

TIPRANKS
·
May 26

Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy

MT Newswires Live
·
May 26

BUZZ-Olema Pharma climbs on collaboration agreement with Bayer

Reuters
·
May 26

Olema, Bayer launch OP-3136 prostate cancer collaboration

TIPRANKS
·
May 26

Olema, Bayer partner to test OP-3136 with Nubeqa in metastatic prostate cancer trial

Reuters
·
May 26

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement With Bayer to Evaluate Op-3136 in Combination With Nubeqa® (Darolutamide) in Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
May 26

Olema Pharmaceuticals Inc - Study to Evaluate Op-3,136 and Darolutamide in 36 Patients, Initiation Expected in H2 2026

THOMSON REUTERS
·
May 26